Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 11/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.56 |
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | HRH2 | P25021 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486754 | 0.91 | CHRM3 (0.53) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL14696914 | 0.87 | CHRM2 (0.56) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL14696913 | 0.87 | CHRM2 (0.56) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL814972 | 0.87 | CHRM2 (0.72) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL14709881 | 0.87 | CHRM2 (0.72) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Desfesoterodine SCHEMBL14696972 | 0.86 | CHRM2 (0.62) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL2166483 | 0.86 | CHRM2 (0.62) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL8432689 | 0.86 | CHRM3 (0.62) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| Fumaric Acid SCHEMBL19212481 | 0.86 | CHRM3 (0.62) | CHRM3CHRM2CHRM1CHRM5HRH1 | |
| SCHEMBL9922432 | 0.86 | CHRM2 (0.62) | CHRM3CHRM2CHRM1CHRM5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751828-B2 | Antimuscarinic compound having a low content of impurities | DIPHARMA FRANCIS S.R.L. (IT) | 2017-09-05 | — | — | US | disclosed |
| US-9751828-B2 | Antimuscarinic compound having a low content of impurities | DIPHARMA FRANCIS S.R.L. (IT) | 2017-09-05 | — | — | US | disclosed |
| US-9440910-B2 | Reference markers for fesoterodine fumarate | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2016-09-13 | — | — | US | disclosed |
| US-9440910-B2 | Reference markers for fesoterodine fumarate | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2016-09-13 | — | — | US | disclosed |
| US-20160031796-A1 | ANTIMUSCARINIC COMPOUND HAVING A LOW CONTENT OF IMPURITIES | DIPHARMA FRANCIS S.R.L. (IT) | 2016-02-04 | — | — | US | disclosed |
| US-20160031796-A1 | ANTIMUSCARINIC COMPOUND HAVING A LOW CONTENT OF IMPURITIES | DIPHARMA FRANCIS S.R.L. (IT) | 2016-02-04 | — | — | US | disclosed |
| US-20150175526-A2 | THE NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2015-06-25 | — | — | US | disclosed |
| US-20150175526-A2 | THE NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2015-06-25 | — | — | US | disclosed |
| US-20140374284-A1 | NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | ALEMBIC PHARMACEUTICALS LTD (IN) | 2014-12-25 | — | — | US | disclosed |
| US-20140374284-A1 | NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | ALEMBIC PHARMACEUTICALS LTD (IN) | 2014-12-25 | — | — | US | disclosed |
| WO-2013046194-A2 | THE NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140374284-A1 | NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | SHBG, KLK3, FES | CHRM3 268/4885CHRM2 230/4885CHRM1 928/4885 |
| US-20160031796-A1 | ANTIMUSCARINIC COMPOUND HAVING A LOW CONTENT OF IMPURITIES | ADRA2B, ADRB2, ADRA1B | CHRM3 4/4885CHRM2 9/4885CHRM1 60/4885 |
| US-20150175526-A2 | THE NOVEL REFERENCE MARKERS FOR FESOTERODINE FUMARATE | SHBG, FES, KLK3 | CHRM3 146/4885CHRM2 163/4885CHRM1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.